drugset / Trial / NCT00547547
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Brassica juncea that contains high amounts of selenium may slow the growth of cancer cells. Drugs used in chemotherapy, such as irinotecan and capecitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving high-selenium Brassica juncea together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of high-selenium Brassica juncea and capecitabine when given together with irinotecan in treating patients with advanced cancer.
Timeline
- Start
- 2006-04
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brassica juncea | Unknown | 3200 ug | Oral |
| Subject | Brassica juncea | Unknown | 4800 ug | Oral |
| Subject | Brassica juncea | Unknown | 6400 ug | Oral |
| Subject | Brassica juncea | Unknown | 7200 ug | Oral |
| Subject | Brassica juncea | Unknown | 8000 ug | Oral |
| Subject | Capecitabine | Small molecule | 750 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 100 mg/m2 | Intravenous |